Screener
Vertex Pharmaceuticals VRTX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 86%-0.1pp | 86.2%+0.2pp | 86.2%+0.1pp | 86.3%+0.2pp | 86.1%-0.3pp | |
| Operating margin | 38%— | 38.3%— | 34.8%— | —— | —— | |
| Net margin | 35%— | 35.5%— | 32.9%— | —— | —— | |
| Returns | ||||||
| Return on equity | 23.5%— | 24.2%— | 22.5%— | —— | —— | |
| Return on invested capital | 28.4%+1.4pp | 26.8%+32.2pp | 24.3%+24.9pp | 25.7%+26.9pp | 27%+28.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | |
| Liquidity | ||||||
| Current ratio | 3.2×+0.7× | 3×+0.4× | 2.9×+0.2× | 2.4×-0.1× | 2.5×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $79.34+19.6% | $75.54+18.8% | $72.35+13.7% | $67.23+12.3% | $66.34+15.9% | |
| Valuation | ||||||
| Market capitalization | $128.44B+22.5% | $113.44B-8.9% | $115.03B+10.9% | $100.41B-16.3% | $115.63B-4.5% | |
| Price / earnings | 29.2×— | 26.1×— | 29.1×— | —— | —— | |
| Price / sales | 10.2×+1.3× | 9.3×-1.9× | 9.6×+0.2× | 8.6×-2.7× | 10.1×-1.6× | |
| Price / book | 6.3×+0.3× | 5.9×-1.7× | 6.2×-0.2× | 5.8×-1.9× | 6.7×-1.5× |
FAQ
- What are Vertex Pharmaceuticals's profit margins?
- Vertex Pharmaceuticals (VRTX) runs a 86.0% gross margin and a 38.0% operating margin, with a 35.0% net margin.
- Where do Vertex Pharmaceuticals's ratios come from?
- Every ratio is computed from Vertex Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
